Literature DB >> 4111365

Ontogeny of the human complement system: in vitro biosynthesis of individual complement components by fetal tissues.

H R Colten.   

Abstract

The human fetal liver is capable of synthesizing the biologically active form of the second (C2) and fourth (C4) components of complement as early as 8 wk after conception, and the inhibitor of C1 (C1 INH) as early as 11 wk after conception. Biologically active C3 was produced in vitro by fetal liver obtained at 14 wk gestation. These conclusions were based on the observations that isolated fetal livers produced biologically active C2, C3, C4, and C1 INH, that this production was temperature dependent and reversibly inhibited by well-known inhibitors of protein synthesis, and that (14)C-labeled amino acids were incorporated into proteins immunochemically identical with these proteins. The data suggested that a large mononuclear cell was the cell type in the fetal liver that synthesized C2 and C4.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4111365      PMCID: PMC302184          DOI: 10.1172/JCI106866

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  10 in total

1.  Immune hemolysis: a simplified method for the preparation of EAC'4 with guinea pig or with human complement.

Authors:  T Borsos; H J Rapp
Journal:  J Immunol       Date:  1967-08       Impact factor: 5.422

2.  Ontogenesis of two components of human complement: beta1E and beta1C-1A globulins.

Authors:  M Adinolfi; B Gardner; C B Wood
Journal:  Nature       Date:  1968-07-13       Impact factor: 49.962

3.  C1 inhibitor: evidence for decreased hepatic synthesis in hereditary angioneurotic edema.

Authors:  A M Johnson; C A Alper; F S Rosen; J M Craig
Journal:  Science       Date:  1971-08-06       Impact factor: 47.728

4.  The stoichiometric measurement of the serum inhibition of the first component of complement by the inhibition of immune hemolysis.

Authors:  I Gigli; S Ruddy; K F Austen
Journal:  J Immunol       Date:  1968-06       Impact factor: 5.422

5.  The response in vitro of human lymphocytes to phytohemagglutinin and to antigens after fractionation on discontinuous density gradients of albumin.

Authors:  C S August; E Merler; D O Lucas; C A Janeway
Journal:  Cell Immunol       Date:  1970-12       Impact factor: 4.868

6.  Synthesis of the second component of guinea pig complement in vitro.

Authors:  D J Rubin; T Borsos; H J Rapp; H R Colten
Journal:  J Immunol       Date:  1971-02       Impact factor: 5.422

7.  Immune hemolysis and the functional properties of the second (C2) and fourth (C4) components of complement. 3. The hemolytic efficiency of human and guinea pig C2 and C4.

Authors:  W Opferkuch; H J Rapp; H R Colten; T Borsos
Journal:  J Immunol       Date:  1971-04       Impact factor: 5.422

8.  Human C'3: evidence for the liver as the primary site of synthesis.

Authors:  C A Alper; A M Johnson; A G Birtch; F D Moore
Journal:  Science       Date:  1969-01-17       Impact factor: 47.728

9.  Development of gamma G, gamma A, gamma M, beta IC-beta IA, C 1 esterase inhibitor, ceruloplasmin, transferrin, hemopexin, haptoglobin, fibrinogen, plasminogen, alpha 1-antitrypsin, orosomucoid, beta-lipoprotein, alpha 2-macroglobulin, and prealbumin in the human conceptus.

Authors:  D Gitlin; A Biasucci
Journal:  J Clin Invest       Date:  1969-08       Impact factor: 14.808

10.  Synthesis of the first component of human complement in vitro.

Authors:  H R Colten; J M Gordon; T Borsos; H J Rapp
Journal:  J Exp Med       Date:  1968-10-01       Impact factor: 14.307

  10 in total
  20 in total

1.  Human complement C7 and C9 in fetal and newborn sera.

Authors:  M Adinolfi; S E Beck
Journal:  Arch Dis Child       Date:  1975-07       Impact factor: 3.791

2.  Differences between plasma and serum complement in patients with chronic liver disease.

Authors:  S Inai; H Kitamura; T Fujita; J Kojima; K Nagaki
Journal:  Clin Exp Immunol       Date:  1976-09       Impact factor: 4.330

3.  Pulmonary alveolar type II epithelial cells synthesize and secrete proteins of the classical and alternative complement pathways.

Authors:  R C Strunk; D M Eidlen; R J Mason
Journal:  J Clin Invest       Date:  1988-05       Impact factor: 14.808

4.  Immunologic and genetic factors influencing reproduction. A review.

Authors:  T J Gill; C F Repetti
Journal:  Am J Pathol       Date:  1979-05       Impact factor: 4.307

5.  Serum complement level in workers exposed to nebzene, toluene and xylene.

Authors:  R Smolik; K Grzybek-Hryncewicz; A Lange; W Zatoński
Journal:  Int Arch Arbeitsmed       Date:  1973-07-10

Review 6.  Complement biosynthesis by mononuclear phagocytes.

Authors:  A R McPhaden; K Whaley
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

7.  Ontogeny of the third component of complement of Japanese quails.

Authors:  C Kai; Y Yoshikawa; K Yamanouchi; H Okada; S Morikawa
Journal:  Immunology       Date:  1985-03       Impact factor: 7.397

8.  Isolation of cDNA clones for the human complement protein factor B, a class III major histocompatibility complex gene product.

Authors:  D E Woods; A F Markham; A T Ricker; G Goldberger; H R Colten
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

9.  Fragment Bb in amniotic fluid: evidence for complement activation by the alternative pathway in women with intra-amniotic infection/inflammation.

Authors:  Edi Vaisbuch; Roberto Romero; Offer Erez; Shali Mazaki-Tovi; Juan Pedro Kusanovic; Kusanovic Juan Pedro; Eleazar Soto; Francesca Gotsch; Zhong Dong; Tinnakorn Chaiworapongsa; Sun Kwon Kim; Pooja Mittal; Percy Pacora; Lami Yeo; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2009-10

10.  Complement biosynthesis by the human hepatoma-derived cell line HepG2.

Authors:  K M Morris; D P Aden; B B Knowles; H R Colten
Journal:  J Clin Invest       Date:  1982-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.